U.S. flag

An official website of the United States government

Format
Items per page

Send to:

Choose Destination

Links from PMC

Items: 7

1.

Neutropenia

An abnormally low number of neutrophils in the peripheral blood. [from HPO]

MedGen UID:
163121
Concept ID:
C0853697
Finding
2.

Leukopenia

An abnormal decreased number of leukocytes in the blood. [from HPO]

MedGen UID:
6073
Concept ID:
C0023530
Disease or Syndrome
3.

Agranulocytosis

Marked decrease in the number of granulocytes. [from HPO]

MedGen UID:
7932
Concept ID:
C0001824
Disease or Syndrome
4.

Leukocyte disorder

A disease involving leukocytes. [from MONDO]

MedGen UID:
7325
Concept ID:
C0023510
Disease or Syndrome
5.

Gastrointestinal defects and immunodeficiency syndrome 2

PI4KA-related disorder is a clinically variable disorder characterized primarily by neurologic dysfunction (limb spasticity, developmental delay, intellectual disability, seizures, ataxia, nystagmus), gastrointestinal manifestations (multiple intestinal atresia, inflammatory bowel disease), and combined immunodeficiency (leukopenia, variable immunoglobulin defects). Age of onset is typically antenatal or in early childhood; individuals can present with any combination of these features. Rare individuals present with later-onset hereditary spastic paraplegia. Brain MRI findings can include hypomyelinating leukodystrophy, cerebellar hypoplasia/atrophy, thin or dysplastic corpus callosum, and/or perisylvian polymicrogyria. [from GeneReviews]

MedGen UID:
1811526
Concept ID:
C5676901
Disease or Syndrome
6.

Cisplatin toxicity

MedGen UID:
995845
Concept ID:
CN315609
Disease or Syndrome
7.

Fluorouracil response

5-fluorouracil is a chemotherapeutic agent, and a member of the fluoropyrimidine group of substances. It is mainly used to treat solid tumors, such as colorectal, breast and aerodigestive cancers. Dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene) is the rate-limiting enzyme for fluoropyrimidine metabolism and is therefore responsible for the detoxification of these types of drugs. Patients who are homozygous for variants in DPYD that lead to a non-functional protein, such as *2A or *13, have a high risk of severe or fatal drug toxicities and may benefit from receiving an alternative chemotherapeutic drug. Patients heterozygous for these variants also have an increased risk for drug toxicities, and reduced dosing is recommended for these individuals. Guidelines regarding the use of pharmacogenomic tests in dosing for 5-fluorouracil have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC) and are available on the PharmGKB website. [from PharmGKB]

MedGen UID:
450455
Concept ID:
CN077983
Sign or Symptom
Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...